ArticleTranslational cancer research2025
Investigation into the sensitivity of adipocytes mediated by the major vault protein (MVP) to chemotherapy for triple-negative breast cancer.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chemotherapy is an important therapeutic method for treating triple-negative breast cancer (TNBC), and docetaxel is the most commonly used chemotherapy drug for TNBC. Fat cells may increase the aggressiveness of TNBC and reduce the therapeutic effect of docetaxel. This research aimed to examine the mechanisms underlying the reduced chemosensitivity of TNBC to docetaxel. Methods: Cell migration and invasion experiments revealed that breast cancer cells cocultured with mature adipocytes had increased invasive and migratory capabilities, and decreased sensitivity to docetaxel chemotherapy. Immunofluorescence and Western blot analyses revealed the significant upregulation of major vault protein (MVP) expression in the cocultured breast cancer cells. Results: Our findings indicated that docetaxel effectively inhibited the proliferation, migration, and invasion of the MDA-MB231 cells. The optimal therapeutic concentration for the MDA-MB231 cells was 1,000 nM, and the optimal treatment duration was 48 hours. Conclusions: The level of MVP expression appears to influence the chemosensitivity of breast cancer cells to docetaxel. Notably, our results suggest that cocultured breast cancer cells may modulate MVP expression via the Notch1 signaling pathway. Overall, this study provides evidence that adipocytes could influence the chemosensitivity of TNBC cells to docetaxel via MVP expression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.